CRDF at a glance
Cardiff Oncology, Inc. (CRDF, SEC CIK 1213037) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 14, 2026 and Form 4 insider filings as recently as July 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cardiff Oncology, Inc. (CRDF) reported revenue of $593,000 (down 13.2% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$0.69.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Cardiff Oncology, Inc. (CRDF) shares worth $11.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by PACE GARY W on July 14, 2026 of 687,285 shares at $1.46 per share.
- In the last 90 days, CRDF insiders reported 2 open-market purchases ($1.0M) and 0 open-market sales ($0) on Form 4, a net purchase of $1.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $593K
- −13.2% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$1.0M
- 13F holders
- 23 funds
- $11.9M · −3 vs prior quarter
- Latest 8-K
- Sep 14, 2026
- Item 1.01 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New litigation risk: Cardiff sued NMS over alleged wrongful termination of the onvansertib license agreement; NMS filed counterclaims
- Most material business risk: Validated termination could eliminate exclusive rights to onvansertib intellectual property
- Regulatory or legal risk: Failure to obtain preliminary injunctive relief could permit NMS to enforce termination during litigation
- Operational risk: Litigation may divert senior-management resources from strategic priorities for multiple years
- Financial risk: Pending litigation could restrict access to equity or debt financing on favorable terms
AI summary of the CRDF 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Litigation resolved with prejudice through mutual releases and no monetary payment by either party
- Onvansertib license retained, with updated exclusivity restricting Nerviano from competing during the royalty term
Item 7.01: Regulation FD Disclosure
- Section 18 Exchange Act liability disclaimer for the disclosed information
- Information excluded from automatic incorporation into future Securities Act or Exchange Act filings
Item EX-99.1: Item EX-99.1
- Settlement resolves all disputes over global onvansertib rights under the 2017 exclusive license agreement
- Cardiff and NMS agreed to mutually release litigation claims and seek dismissal with prejudice
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results and business update announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the financial details and operational update
Item EX-99.1: Item EX-99.1
- Phase 2 CRDF-004 supported advancing 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program
- Confirmed ORR 72.2% versus 42.1% for standard of care, with PFS hazard ratios of 0.55 and 0.57
Item 8.01: Other Events
- Cardiff Oncology priced a securities offering on July 15, 2026
- Offering proceeds and security terms require review of Exhibit 99.1
Item 1.01: Entry into a Material Definitive Agreement
- $10.05M gross proceeds from 8.57M shares and warrants, funding working capital and general corporate purposes
- Additional 721,649 insider shares and warrants at $1.455, above the $1.05 institutional purchase price
Item EX-99.1: Item EX-99.1
- $10 million registered direct offering, funding working capital and general corporate purposes
- 8,571,429 shares plus warrants sold at $1.05 per share and warrant, creating substantial equity dilution
AI summaries of CRDF 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRDF
Don't miss the next CRDF filing
- Alerts as it files. A push when CRDF files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRDF, by share count.
- Ask anything. An AI agent that reads every CRDF filing and answers with sources.
CRDF alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| PACE GARY W | Buy | Jul 14, 2026 | 687,285 | $1.46 |
| Mohindru Mani | Buy | Jul 14, 2026 | 34,364 | - |
| Mohindru Mani | Buy | Jul 14, 2026 | 34,364 | $1.46 |
| PACE GARY W | Buy | Jul 14, 2026 | 687,285 | - |
| PACE GARY W | Buy | Jun 18, 2026 | 30,000 | $1.22 |
| Mohindru Mani | Buy | Jun 18, 2026 | 24,703 | $1.21 |
| TANNENBAUM RENEE P | A | Jun 11, 2026 | 40,565 | - |
| Armitage James O | A | Jun 11, 2026 | 40,565 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $683K | $593K |
| Operating Income | - | -$48.7M | -$49.0M |
| Net Income | -$41.4M | -$45.4M | -$45.9M |
| Op. Margin | - | -7123.1% | -8256.3% |
| Net Margin | - | -6651.7% | -7732.0% |
| Balance Sheet | |||
| Total Assets | - | $97.2M | $61.9M |
| Equity | $69.7M | $82.9M | $45.4M |
| ROE | -59.4% | -54.8% | -101.0% |
| Per Share | |||
| EPS | $-0.93 | $-0.95 | $-0.69 |
| Cash Flow | |||
| Operating CF | - | -$37.7M | -$37.9M |
| CapEx | $582K | $80K | $44K |
Source: XBRL data in Cardiff Oncology, Inc. (CRDF)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CRDF share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $11.9M |
| Q1 2026 | 26 | $22.4M |
| Q4 2025 | 22 | $40.6M |
| Q3 2025 | 24 | $28.3M |
| Q2 2025 | 24 | $48.9M |
| Q1 2025 | 20 | $31.6M |
| Q4 2024 | 18 | $33.5M |
| Q3 2024 | 13 | $6.6M |
- AQR Capital Management+280.2K (+424%)
- Morgan Stanley+189.8K (+337%)
- Millennium Management+111.5K (+484%)
- Vanguard Capital Management LLC+39.6K (+1%)
- PNC Financial Services+1.5K (+214%)
- BlackRock−3.01M (-76%)
- State Street Corp−855.6K (-72%)
- Vanguard Portfolio Management LLC−365.2K (-84%)
- Northern Trust−340.3K (-69%)
- Two Sigma Investments−159.3K (-77%)
- Citadel Advisors LLC−125.6K
- T. Rowe Price Group−52.3K
- Invesco Ltd−20.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 170 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRDF filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 8-K | May 29, 2026 | - | Analysis | |
| 8-K | May 19, 2026 | - | Analysis | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 28, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 8-K | Apr 9, 2026 | - | Analysis | - |
| 8-K | Apr 2, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CRDF SEC filings: frequently asked questions
Are CRDF insiders buying or selling?
In the last 90 days, Cardiff Oncology, Inc. (CRDF) officers, directors and 10% owners reported 2 open-market purchases worth $1.0 million by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CRDF stock?
As of June 30, 2026, the largest Cardiff Oncology, Inc. (CRDF) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($3.8 million), Pfizer Inc ($3.0 million), Franklin Resources ($1.6 million), BlackRock ($1.3 million), AQR Capital Management ($450,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRDF's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cardiff Oncology, Inc. (CRDF) reported revenue of $593,000 (down 13.2% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$0.69. The figures come from the XBRL data in the 10-K.
What did CRDF report in its latest 8-K?
Cardiff Oncology, Inc. (CRDF) filed an 8-K on September 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 7.01 (Regulation FD Disclosure). Litigation resolved with prejudice through mutual releases and no monetary payment by either party.
What are the latest CRDF SEC filings?
Cardiff Oncology, Inc. (CRDF) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 14, 2026 and a Form 4 insider filing on July 16, 2026.
What is CRDF's SEC CIK number?
Cardiff Oncology, Inc. (CRDF)'s SEC Central Index Key (CIK) is 1213037. EDGAR lists every CRDF filing under that number.
Ask anything about CRDF
The research agent reads CRDF's filings, financials, insider trades and 13F holders, then answers with sources.